Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
11°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Unicycive Therapeutics, Inc.
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
September 06, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
August 29, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
July 20, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
July 18, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
June 29, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 16, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
May 16, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
April 24, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
March 31, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
March 06, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
February 27, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
February 02, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
January 23, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
January 05, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
December 29, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
December 28, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
December 22, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive to Participate in Upcoming Investor Conferences
November 28, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
November 21, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Announces Third Quarter Financial Results and Provides Business Update
November 14, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
November 10, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
October 26, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference
September 29, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
UNCY
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.